ClinicalTrials.gg
CompletedNCT03959618CIVCAPUpdated Nov 9, 2026Results posted

Intravenous Chemotherapy and Plant-based Dietary Supplements

An observational study in Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut Cancerologie de l'Ouest · Observational

How we know

Updated Nov 9, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest — 7 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Institut Cancerologie de l'Ouest.

Enrollment
6th of 12
200 · median 195
Started
2019
with 6 others
Observational
12 of 35
2 open now
Registered
16th of 35
by date

Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, this one is the 6th largest by enrollment of the 12 observational ones that give a count, is one of 7 that started in 2019, is one of 12 observational ones, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, or all of them as a file.
02

Study summary

More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed.

In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress.

At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives.

Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature).

Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.

Read the detailed description
  • Determine the quantitative impact of the use of dietary supplements by patients with breast cancer and treated in a neo-adjuvant and/or adjuvant condition by IV chemotherapy in day hospital.
  • Determine an over-risk of disruption of liver balance in the population of patients taking Desmodium.
  • Gather a critical mass of relevant information with the objective of carrying out the evaluation and analysis of cancer care practices related to the intake of dietary supplements.
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • dietary supplements
  • Desmodium
  • chemotherapy
  • breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients of the ICO René Gauducheau taken care at day hospital for IV chemotherapy treatment of breast cancer in neoadjuvant and/or adjuvant situation.

Eligibility criteria

Inclusion Criteria:

  • breast cancer treated by intra-venous chemotherapy
  • inclusion at the last cycle (cure)
  • all chemotherapy cycles realised at ICO

Exclusion Criteria:

  • no breast cancer
  • breast cancer
  • not all chemotherapy cycles realised at ICO
  • patient who has not finished his chemotherapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • dietary supplements group with Desmodium

    patients taking dietary supplements with Desmodium

    Other: dietary supplements questionaire · Other: Liver function

  • dietary supplements group without Desmodium

    patients taking dietary supplements without Desmodium

    Other: dietary supplements questionaire · Other: Liver function

  • Control group

    patients not taking any dietary supplements

    Other: Liver function

Interventions

  • Otherdietary supplements questionaire

    Patient questionaire to be completed by the patient at the last cycle

  • OtherLiver function

    Liver blood test to be performed from the first to the last chemotherapy cycle

06

What researchers measure

Primary outcomes

  1. Prevalence of Dietary Supplement Use During IV Chemotherapy

    Number of participants using dietary supplements during IV chemotherapy, including dietary supplements containing Desmodium and dietary supplements not containing Desmodium, compared with participants not using dietary supplements (control group).

    Time frame: 12 months

Secondary outcomes

  1. Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle

    % of participants with hepatic cytolysis undergoing chemotherapy between the first and last treatments

    Time frame: 12 months

  2. Percentage of Participants Taking Each Type of Dietary Supplement

    Dietary supplement use was extracted from patient-reported products recorded at the last chemotherapy cycle. Participants were classified into 'with Desmodium' and 'without Desmodium' groups based on the presence of Desmodium-containing products. Supplement categories (homeopathy, phytotherapy, aromatherapy, vitamin supplementation, mineral supplementation, probiotics, and gemmotherapy) were not mutually exclusive. Participants could report the use of more than one type of dietary supplement; therefore, percentages may total more than 100% within a group.

    Time frame: 12 months

07

Results

Posted Nov 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneControl GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With Desmodium
Started1018217
Completed1018217
Not completed000

Outcome measures

PrimaryPrevalence of Dietary Supplement Use During IV Chemotherapy

Number of participants using dietary supplements during IV chemotherapy, including dietary supplements containing Desmodium and dietary supplements not containing Desmodium, compared with participants not using dietary supplements (control group).

Time frame:
12 months
Reported as:
Count of participants · Participants
Prevalence of Dietary Supplement Use During IV Chemotherapy
ParticipantsControl GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With Desmodium
Prevalence of Dietary Supplement Use During IV Chemotherapy08217
SecondaryIncidence of Hepatic Cytolysis From the First to the Last Treatment Cycle

% of participants with hepatic cytolysis undergoing chemotherapy between the first and last treatments

Time frame:
12 months
Reported as:
Number · Percentage of participants
Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle
Percentage of participantsControl GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With Desmodium
Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle30.731.756.3
SecondaryPercentage of Participants Taking Each Type of Dietary Supplement

Dietary supplement use was extracted from patient-reported products recorded at the last chemotherapy cycle. Participants were classified into 'with Desmodium' and 'without Desmodium' groups based on the presence of Desmodium-containing products. Supplement categories (homeopathy, phytotherapy, aromatherapy, vitamin supplementation, mineral supplementation, probiotics, and gemmotherapy) were not mutually exclusive. Participants could report the use of more than one type of dietary supplement; therefore, percentages may total more than 100% within a group.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Taking Each Type of Dietary Supplement
Percentage of participantsControl GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With Desmodium
Homeopathy01829
Phytotherapy049100
Aromatherapy02429
Vitamin therapy02218
Mineral supplementation01212
Probiotics0106
Gemmotherapy010

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Group———
Dietary Supplements Group Without Desmodium———
Dietary Supplements Group With Desmodium———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Control GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With DesmodiumTotal
Median57 (44 to 67)49 (43 to 59)56 (42 to 58)52 (43 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)Control GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With DesmodiumTotal
Female1018217200
Male0000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Control GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With DesmodiumTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(participants)Control GroupDietary Supplements Group Without DesmodiumDietary Supplements Group With DesmodiumTotal
France1018217200
08

Study locations

1 site
  • Institut de Cancerologie de L'Ouest
    Saint-Herblain, 44805, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2020, 13 months.

Results were first posted in Nov 2026, 6 years 5 months after primary completion.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 13 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 22, 2019
StartActual
Apr 2, 2019
Primary completionActual
May 13, 2020
CompletionActual
May 13, 2020
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Sites
1 site added, 1 site removed
Show site
  • Institut de Cancerologie de L'Ouest · Saint-Herblain, France
Show 1 removed
  • Institut de Cancerologie de L'Ouest · Saint Herblain, France
Nov 9, 2026
Interventions
Changed dietary supplements questionary→dietary supplements questionaire. Added Liver function. Arm changed dietary supplements group→dietary supplements group with Desmodium. Arms added: dietary supplements group without Desmodium·Control group
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Editedevaluate quantitatively the usePrevalence of dietary supplements in patients duringDietary Supplement Use During IV chemotherapyChemotherapyTime frame: 12 months
Nov 9, 2026
Secondary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedIncidence of Hepatic Cytolysis From the First to the Last Treatment CycleTime frame: 12 months
  • AddedPercentage of Participants Taking Each Type of Dietary SupplementTime frame: 12 months
  • RemovedEvaluate the impact of taking Desmodium between the first and last cycle of treatmentTime frame: 12 months
  • RemovedDescription of dietary supplements takenTime frame: 12 months
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Institut de Cancerologie de L'Ouest · Saint-Herblain, France
    Show 1 removed
    • Institut de Cancerologie de L'Ouest · Saint Herblain, France
    Primary outcomes 1 edited
    What changed in the outcomes
    • Editedevaluate quantitatively the usePrevalence of dietary supplements in patients duringDietary Supplement Use During IV chemotherapyChemotherapyTime frame: 12 months
    Secondary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedIncidence of Hepatic Cytolysis From the First to the Last Treatment CycleTime frame: 12 months
    • AddedPercentage of Participants Taking Each Type of Dietary SupplementTime frame: 12 months
    • RemovedEvaluate the impact of taking Desmodium between the first and last cycle of treatmentTime frame: 12 months
    • RemovedDescription of dietary supplements takenTime frame: 12 months
    Interventions Changed dietary supplements questionary→dietary supplements questionaire. Added Liver function. Arm changed dietary supplements group→dietary supplements group with Desmodium. Arms added: dietary supplements group without Desmodium·Control group

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03959618
Responsible party
Sponsor
First posted
May 22, 2019
Start date
Apr 2, 2019
Primary completion
May 13, 2020
Completion
May 13, 2020
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Study contacts

Emmanuelle BOURBOULOUX, MD
principal investigator · ICO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion